Tagrix40 mg

Tagrix is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors have specific EGFR mutations. Indications are classified below by strength of evidence and setting.

Established / FDA-Approved Indications

• First-line treatment of metastatic NSCLC: As monotherapy in adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an approved test.
• First-line combination therapy: In combination with pemetrexed and platinum-based chemotherapy for first-line treatment of the same EGFR exon 19 deletion or exon 21 L858R metastatic NSCLC population (combination therapy required for this indication; not for use as monotherapy in this specific regimen).
• Adjuvant treatment: Following tumor resection in adult patients with early-stage (Stage IB-IIIA) EGFR exon 19 deletion or exon 21 L858R mutation-positive NSCLC.
• Locally advanced, unresectable (Stage III) NSCLC: In patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive disease whose disease has not progressed during or following platinum-based chemoradiation therapy.
• Second-line, mutation-specific treatment: Treatment of metastatic EGFR T790M mutation-positive NSCLC, as detected by an approved test, in patients whose disease has progressed on or after prior EGFR TKI therapy.

All indications require confirmed, specific EGFR mutation status (exon 19 deletion, exon 21 L858R, or T790M as applicable) prior to starting treatment; Tagrix is a biomarker-directed therapy and is not appropriate for EGFR-mutation-negative or untested NSCLC.

Each film-coated tablet contains Osimertinib (as osimertinib mesylate) equivalent to 40 mg or 80 mg of osimertinib base, along with standard pharmaceutical excipients for oral tablet formulation.

Tagrix is an orally administered, third-generation, irreversible EGFR tyrosine kinase inhibitor developed specifically to target both common EGFR-activating mutations (exon 19 deletions, exon 21 L858R) and the T790M resistance mutation that commonly develops after treatment with earlier-generation EGFR TKIs. It is used in the targeted treatment of EGFR-mutated non-small cell lung cancer as part of precision oncology care.

Tagrix belongs to the class of antineoplastic agents known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (third generation), used in targeted cancer therapy.

Osimertinib is a small-molecule, irreversible inhibitor of EGFR tyrosine kinase. It covalently binds to EGFR harboring sensitizing mutations (exon 19 deletion, L858R) as well as the T790M resistance mutation, blocking downstream signaling pathways that drive tumor cell proliferation and survival. Compared with earlier-generation EGFR TKIs, Osimertinib has greater selectivity for mutant over wild-type EGFR, which is thought to reduce (though not eliminate) certain EGFR-related toxicities. Peak plasma concentrations are reached several hours after oral dosing, the drug is highly protein bound, is metabolized predominantly by CYP3A4/CYP3A5, and has an elimination half-life of approximately 48 hours, supporting once-daily dosing.

Tagrix tablets should be swallowed whole with water and should not be crushed, split, or chewed. For patients unable to swallow tablets, the tablet may be dispersed in 60 mL (2 ounces) of non-carbonated water only (no other liquids), stirred until dispersed, and the resulting mixture swallowed immediately; the container should then be rinsed with an additional half-glass of water and swallowed to ensure the full dose is taken. Do not crush, heat, or dissolve in other liquids.

Tagrix is primarily metabolized by CYP3A4, and clinically significant interactions include:

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): significantly reduce plasma concentrations of Tagrix, which may reduce its efficacy. Concomitant use should be avoided; if unavoidable, a dose increase of Tagrix may be considered under physician supervision.
• Strong CYP3A4 inhibitors: May increase plasma concentrations of Tagrix; no dose adjustment is generally required based on available data, but patients should be monitored for increased adverse effects.
• QT-prolonging drugs: Concomitant use with other medications known to prolong the QT interval may have an additive effect on QT prolongation; avoid combination where possible or monitor ECG closely.
• BCRP transporter substrates: Tagrix inhibits the BCRP transporter and may increase systemic exposure of co-administered BCRP substrate drugs; monitor for toxicity of the affected drug.

Very Common

• Diarrhea
• Rash and dry skin
• Nail toxicity (including paronychia)
• Stomatitis (mouth ulcers/inflammation)
• Fatigue
• Musculoskeletal pain
• Laboratory abnormalities: reduced white blood cell count (leukopenia, lymphopenia, neutropenia), low platelet count (thrombocytopenia), anemia

Serious Adverse Effects (Require Prompt Medical Attention)

• Interstitial lung disease (ILD)/pneumonitis: Can be severe and, in rare cases, fatal. Seek prompt evaluation for any new or worsening respiratory symptoms such as shortness of breath, cough, or fever.
• QT interval prolongation: May increase risk of abnormal heart rhythms; symptoms such as palpitations, dizziness, or fainting should be reported immediately.
• Cardiomyopathy/reduced heart pumping function (reduced ejection fraction): May present as shortness of breath, swelling of legs/ankles, or fatigue.
• Keratitis (eye inflammation): May present as eye pain, redness, light sensitivity, blurred vision, or excessive tearing; requires prompt ophthalmology referral.

Pregnancy: Tagrix can cause fetal harm based on animal reproduction studies and its mechanism of action. It should not be used during pregnancy. Females of reproductive potential should use effective contraception during treatment with Tagrix and for a period after the final dose as advised by their physician; male patients with female partners of reproductive potential should also use effective contraception. If pregnancy occurs during treatment, the patient should be advised of the potential risk to the fetus and consult her physician immediately.

Lactation: It is not known whether Tagrix passes into human breast milk, but due to the potential for serious adverse effects in a breastfeeding infant, breastfeeding is not recommended during treatment with Tagrix and for a period after the last dose. Consult a physician before breastfeeding.

Tagrix carries several important warnings requiring careful patient monitoring:

Interstitial Lung Disease (ILD)/Pneumonitis

ILD/pneumonitis has occurred in patients treated with Tagrix and can be severe or fatal. The risk may be increased in patients previously treated with chemoradiation. Promptly evaluate any patient with new or worsening respiratory symptoms (dyspnea, cough, fever); withhold treatment if ILD/pneumonitis is suspected and permanently discontinue if confirmed (per physician assessment of severity).

Cardiotoxicity

QT interval prolongation and cardiomyopathy (reduced left ventricular ejection fraction) have been reported. Obtain a baseline electrocardiogram and echocardiogram/MUGA scan, particularly in patients with cardiac risk factors, and monitor periodically during treatment. Use with caution, or avoid, in combination with other QT-prolonging drugs. See Contraindications for hypersensitivity information.

Keratitis

Refer patients with signs/symptoms of keratitis (eye pain, redness, light sensitivity, blurred vision) promptly for ophthalmologic evaluation.

Embryo-Fetal Toxicity

See Pregnancy and Lactation for detailed guidance on fetal risk and contraception.

Biomarker Testing Requirement

Confirmed EGFR mutation status (exon 19 deletion, exon 21 L858R, or T790M as relevant to the indication) using an approved test is required before initiating Tagrix, as this is a biomarker-directed targeted therapy.

There is limited clinical experience with Tagrix overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Management should consist of general supportive measures, discontinuation of the drug, and close monitoring of cardiac function (including ECG for QT prolongation) and other vital signs, as clinically indicated. There is no specific antidote for Tagrix overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No dose adjustment is required in mild to moderate renal impairment. Data in severe renal impairment are limited; use with caution and monitor closely.

Hepatic Impairment

No dose adjustment is required in mild to moderate hepatic impairment. Data in severe hepatic impairment are limited; use with caution and monitor closely.

Geriatric Use

No overall differences in effectiveness have been observed between elderly and younger patients; no dose adjustment is required based on age alone, though elderly patients may be more susceptible to certain adverse effects.

Pediatric Use

Safety and efficacy of Tagrix in pediatric patients have not been established.

Duration of treatment with Tagrix depends on the indication: in the adjuvant setting after tumor resection, treatment is typically continued for up to 3 years or until disease recurrence or unacceptable toxicity, whichever occurs first. In metastatic disease (first-line or T790M-positive second-line) and in unresectable Stage III disease after chemoradiation, treatment is continued until disease progression or unacceptable toxicity occurs. The exact duration should be determined by the treating oncologist based on individual response and tolerability.

Osimertinib is classified as a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor within the broader class of targeted antineoplastic (anticancer) agents.

Osimertinib works by irreversibly and selectively binding to EGFR molecules that carry specific activating mutations (exon 19 deletion or L858R) and the T790M resistance mutation, blocking the kinase activity of the receptor. This interrupts downstream signaling cascades (such as the RAS/MAPK and PI3K/AKT pathways) that drive uncontrolled tumor cell growth and survival, leading to reduced tumor proliferation. Its selectivity for mutant over wild-type EGFR is intended to spare some normal tissue EGFR signaling.

The safety and efficacy of Tagrix have not been established in pediatric patients. Tagrix is currently indicated only for use in adult patients with EGFR-mutated non-small cell lung cancer, and it should not be used in children or adolescents outside of a clinical trial setting.